Xendo is a leading independent consultancy and project management organisation in the fields of pharmaceutical products, medical devices and healthcare. Sovereign has backed the management team to further develop the business through a strategy of organic and acquisitive growth.

The Eversheds corporate team was led by partner James Trevis and comprised: associate Alex McCarney in London, partner Tom van Wijngaarden and associate Youssef Rasnabe in the Netherlands and partner Sven Schweneke and associate Sebastian Buchholz in Germany. The banking team led by partner Jason Wurzal working alongside senior associate Lucas Lustermans and associate Wouter Folkers in the Netherlands and Jennifer Hock in Germany. Deal structuring and tax advice was provided by partner Ben Jones and senior associate Colin Askew.

Partner James Trevis commented:

“This is an important investment in a key sub sector and we are delighted to have followed our previous involvement with Sovereign on investments such as Dalepak by advising them on this investment. We look forward to supporting the team on their exciting buy and build strategy as they look to expand the Xendo operations”.

Sovereign Capital’s partner Dominic Dalli commented:

“It was great to work with the Eversheds team again who were able to utilise their international offering in order to get this complex transaction across the finishing line.”

Founded in 1990 and employing over 140 experienced and highly educated professionals, Xendo operates from three countries in Europe (UK, Netherlands and Germany). The business is focused on the complex regulatory compliance requirements of its customers; it provides regulatory affairs compliance, validation and pharmacovigilance consulting and outsourced services to life sciences companies throughout the life cycle of their products.